Recruiting
Phase 1
2023-508476-11-00
A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic, adenoid cystic carcinoma.
Phase 1 – testing safety in a small group of people
Conditions:
Adenoid cystic carcinoma (ACC)
Sponsor: Remix Therapeutics Inc.
trial.available_in:
БГ